Topline data were announced from a phase 3 trial evaluating ceralasertib plus Imfinzi in patients with locally advanced or metastatic NSCLC.

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Nearly 1 in 4 Americans believe the US health care system is in crisis, and high costs are the top reason why.

Of 3306 individuals screened, 806 patients met eligibility criteria and were randomized, 404 to receive mepolizumab and 402 to receive placebo. Two patients (1 in each group) did not initiate their ...

Black and Hispanic/Latino patients with food allergies are less apt to recognize anaphylaxis and have more limited EAI access than White patients.

Tezepelumab may allow patients with severe, uncontrolled asthma who are oral corticosteroid-dependent to decrease their OCS use.

The poll found 82% of US adults are satisfied with their health insurance overall; about 1 in 3 said they are very satisfied. HealthDay News — Most people in the United States are happy with their ...

Severe obstruction prebronchodilator prevalence increased with age and was higher for middle-aged adults compared with children and young adults. Severe airflow obstruction was prevalent in children ...

A Prescription Drug User Fee Act target date of October 30, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...